Loading…

The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil

Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2007-02, Vol.120 (3), p.694-701
Main Authors: Jensen, Søren Astrup, Vainer, Ben, Sørensen, Jens Benn
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3
cites cdi_FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3
container_end_page 701
container_issue 3
container_start_page 694
container_title International journal of cancer
container_volume 120
creator Jensen, Søren Astrup
Vainer, Ben
Sørensen, Jens Benn
description Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive patients were analysed for the expression of TS and DPD using immunohistochemistry. All patients were completely resected for colorectal cancer stages II–III and have subsequently received adjuvant treatment with 5‐FU. In a multivariate analysis adjusting for the impact of bowel obstruction and vascular tumour invasion, diffuse TS pattern was significantly associated with increased risk of recurrence (hazard ratio (HR) = 1.9; 95% confidence interval (CI): 1.1–3.2; p = 0.02), but without significant association to death (HR = 1.6; 95% CI: 0.9–2.8; p = 0.08). High TS intensity was not significantly associated with lower risk of recurrence (HR = 0.6; 95% CI: 0.3–1.1; p = 0.07) or death (HR = 0.6; 95% CI: 0.3–1.2; p = 0.2). High DPD intensity was significantly associated with increased risk of recurrence (HR = 1.5; 95% CI: 1.1–2.3; p = 0.03) and death (HR = 1.6; 95% CI: 1.1–2.5; p = 0.02). Patients with a combination of low TS and high DPD intensity were at significantly increased risk of both recurrence (HR = 2.1; 95% CI: 1.0–4.2; p = 0.04) and death (HR = 2.0; 95% CI: 1.0–4.0; p = 0.05). No relationship between tolerability and toxicity of 5‐FU and TS and DPD expression was found. It is concluded that characterizing colorectal carcinomas by TS and DPD expression may disclose subsets of patients with significantly greater risk of disease recurrence and early death. This may be utilized in the selection of patients for treatment approaches and for decision on follow‐up programs. © 2006 Wiley‐Liss, Inc.
doi_str_mv 10.1002/ijc.22318
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20618803</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20618803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3</originalsourceid><addsrcrecordid>eNp10ctu1DAUBmALgehQWPACyBsqsUjryyRxlmhUoKhSN-06cuzjiUcee7Adqux4hL5EX4wnwXORumJl6fjTf6TzI_SRkktKCLuyG3XJGKfiFVpQ0rUVYbR-jRblj1Qt5c0ZepfShhBKa7J8i85oS7qG12yBnu9HwLsY1j6kbBVOdu2tsUp6BTgYnMd5a_XsZAacZp9HmQBLr7G246xj2M3RFmA9YA2HyRr83liPVXAhgsrS4UNe3AdywvFOZgs-Jyz1ZvotfXYzzhHKDo0fbR5x_ffPk3FTiGGKUln3Hr0x0iX4cHrP0cO36_vVj-r27vvN6uttpZa0E9VSa8X5wBlIQUTXSQZKK9OqgXemJaoeBFfCDEyCkQQGgI4aqBveNnXTEcPP0cUxt1zk1wQp91ubFDgnPYQp9Yw0VAjCC_xyhCqGlCKYflfuIOPcU9LvO-lLJ_2hk2I_nUKnYQv6RZ5KKODzCcikpDOxHMumFyd4XQvWFXd1dI_Wwfz_jf3Nz9Vx9T87xqk_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20618803</pqid></control><display><type>article</type><title>The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Jensen, Søren Astrup ; Vainer, Ben ; Sørensen, Jens Benn</creator><creatorcontrib>Jensen, Søren Astrup ; Vainer, Ben ; Sørensen, Jens Benn</creatorcontrib><description>Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive patients were analysed for the expression of TS and DPD using immunohistochemistry. All patients were completely resected for colorectal cancer stages II–III and have subsequently received adjuvant treatment with 5‐FU. In a multivariate analysis adjusting for the impact of bowel obstruction and vascular tumour invasion, diffuse TS pattern was significantly associated with increased risk of recurrence (hazard ratio (HR) = 1.9; 95% confidence interval (CI): 1.1–3.2; p = 0.02), but without significant association to death (HR = 1.6; 95% CI: 0.9–2.8; p = 0.08). High TS intensity was not significantly associated with lower risk of recurrence (HR = 0.6; 95% CI: 0.3–1.1; p = 0.07) or death (HR = 0.6; 95% CI: 0.3–1.2; p = 0.2). High DPD intensity was significantly associated with increased risk of recurrence (HR = 1.5; 95% CI: 1.1–2.3; p = 0.03) and death (HR = 1.6; 95% CI: 1.1–2.5; p = 0.02). Patients with a combination of low TS and high DPD intensity were at significantly increased risk of both recurrence (HR = 2.1; 95% CI: 1.0–4.2; p = 0.04) and death (HR = 2.0; 95% CI: 1.0–4.0; p = 0.05). No relationship between tolerability and toxicity of 5‐FU and TS and DPD expression was found. It is concluded that characterizing colorectal carcinomas by TS and DPD expression may disclose subsets of patients with significantly greater risk of disease recurrence and early death. This may be utilized in the selection of patients for treatment approaches and for decision on follow‐up programs. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.22318</identifier><identifier>PMID: 17096352</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Chemotherapy, Adjuvant ; colonic neoplasms ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - pathology ; dihydrouracil dehydrogenase (NADP) ; Dihydrouracil Dehydrogenase (NADP) - metabolism ; disease‐free survival ; Female ; fluorouracil ; Fluorouracil - therapeutic use ; Humans ; Immunohistochemistry ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Pharmacology. Drug treatments ; predictive value of tests ; Prognosis ; Survival Analysis ; survival rate ; thymidylate synthase ; Thymidylate Synthase - metabolism ; Treatment Outcome ; Tumors ; tumour markers, biological</subject><ispartof>International journal of cancer, 2007-02, Vol.120 (3), p.694-701</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3</citedby><cites>FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18355829$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17096352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Søren Astrup</creatorcontrib><creatorcontrib>Vainer, Ben</creatorcontrib><creatorcontrib>Sørensen, Jens Benn</creatorcontrib><title>The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive patients were analysed for the expression of TS and DPD using immunohistochemistry. All patients were completely resected for colorectal cancer stages II–III and have subsequently received adjuvant treatment with 5‐FU. In a multivariate analysis adjusting for the impact of bowel obstruction and vascular tumour invasion, diffuse TS pattern was significantly associated with increased risk of recurrence (hazard ratio (HR) = 1.9; 95% confidence interval (CI): 1.1–3.2; p = 0.02), but without significant association to death (HR = 1.6; 95% CI: 0.9–2.8; p = 0.08). High TS intensity was not significantly associated with lower risk of recurrence (HR = 0.6; 95% CI: 0.3–1.1; p = 0.07) or death (HR = 0.6; 95% CI: 0.3–1.2; p = 0.2). High DPD intensity was significantly associated with increased risk of recurrence (HR = 1.5; 95% CI: 1.1–2.3; p = 0.03) and death (HR = 1.6; 95% CI: 1.1–2.5; p = 0.02). Patients with a combination of low TS and high DPD intensity were at significantly increased risk of both recurrence (HR = 2.1; 95% CI: 1.0–4.2; p = 0.04) and death (HR = 2.0; 95% CI: 1.0–4.0; p = 0.05). No relationship between tolerability and toxicity of 5‐FU and TS and DPD expression was found. It is concluded that characterizing colorectal carcinomas by TS and DPD expression may disclose subsets of patients with significantly greater risk of disease recurrence and early death. This may be utilized in the selection of patients for treatment approaches and for decision on follow‐up programs. © 2006 Wiley‐Liss, Inc.</description><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>colonic neoplasms</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - pathology</subject><subject>dihydrouracil dehydrogenase (NADP)</subject><subject>Dihydrouracil Dehydrogenase (NADP) - metabolism</subject><subject>disease‐free survival</subject><subject>Female</subject><subject>fluorouracil</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>predictive value of tests</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>survival rate</subject><subject>thymidylate synthase</subject><subject>Thymidylate Synthase - metabolism</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>tumour markers, biological</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNp10ctu1DAUBmALgehQWPACyBsqsUjryyRxlmhUoKhSN-06cuzjiUcee7Adqux4hL5EX4wnwXORumJl6fjTf6TzI_SRkktKCLuyG3XJGKfiFVpQ0rUVYbR-jRblj1Qt5c0ZepfShhBKa7J8i85oS7qG12yBnu9HwLsY1j6kbBVOdu2tsUp6BTgYnMd5a_XsZAacZp9HmQBLr7G246xj2M3RFmA9YA2HyRr83liPVXAhgsrS4UNe3AdywvFOZgs-Jyz1ZvotfXYzzhHKDo0fbR5x_ffPk3FTiGGKUln3Hr0x0iX4cHrP0cO36_vVj-r27vvN6uttpZa0E9VSa8X5wBlIQUTXSQZKK9OqgXemJaoeBFfCDEyCkQQGgI4aqBveNnXTEcPP0cUxt1zk1wQp91ubFDgnPYQp9Yw0VAjCC_xyhCqGlCKYflfuIOPcU9LvO-lLJ_2hk2I_nUKnYQv6RZ5KKODzCcikpDOxHMumFyd4XQvWFXd1dI_Wwfz_jf3Nz9Vx9T87xqk_</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Jensen, Søren Astrup</creator><creator>Vainer, Ben</creator><creator>Sørensen, Jens Benn</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20070201</creationdate><title>The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil</title><author>Jensen, Søren Astrup ; Vainer, Ben ; Sørensen, Jens Benn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>colonic neoplasms</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - pathology</topic><topic>dihydrouracil dehydrogenase (NADP)</topic><topic>Dihydrouracil Dehydrogenase (NADP) - metabolism</topic><topic>disease‐free survival</topic><topic>Female</topic><topic>fluorouracil</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>predictive value of tests</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>survival rate</topic><topic>thymidylate synthase</topic><topic>Thymidylate Synthase - metabolism</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>tumour markers, biological</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Søren Astrup</creatorcontrib><creatorcontrib>Vainer, Ben</creatorcontrib><creatorcontrib>Sørensen, Jens Benn</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Søren Astrup</au><au>Vainer, Ben</au><au>Sørensen, Jens Benn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>120</volume><issue>3</issue><spage>694</spage><epage>701</epage><pages>694-701</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Cytotoxic effect of 5‐fluorouracil 5‐FU is mediated through inhibition of thymidylate synthase (TS), and 5‐FU is catabolised by dihydropyrimidine dehydrogenase (DPD). Efficacy of 5‐FU may therefore depend on the TS and DPD activity of colorectal cancer. Archival tumour specimens from 303 consecutive patients were analysed for the expression of TS and DPD using immunohistochemistry. All patients were completely resected for colorectal cancer stages II–III and have subsequently received adjuvant treatment with 5‐FU. In a multivariate analysis adjusting for the impact of bowel obstruction and vascular tumour invasion, diffuse TS pattern was significantly associated with increased risk of recurrence (hazard ratio (HR) = 1.9; 95% confidence interval (CI): 1.1–3.2; p = 0.02), but without significant association to death (HR = 1.6; 95% CI: 0.9–2.8; p = 0.08). High TS intensity was not significantly associated with lower risk of recurrence (HR = 0.6; 95% CI: 0.3–1.1; p = 0.07) or death (HR = 0.6; 95% CI: 0.3–1.2; p = 0.2). High DPD intensity was significantly associated with increased risk of recurrence (HR = 1.5; 95% CI: 1.1–2.3; p = 0.03) and death (HR = 1.6; 95% CI: 1.1–2.5; p = 0.02). Patients with a combination of low TS and high DPD intensity were at significantly increased risk of both recurrence (HR = 2.1; 95% CI: 1.0–4.2; p = 0.04) and death (HR = 2.0; 95% CI: 1.0–4.0; p = 0.05). No relationship between tolerability and toxicity of 5‐FU and TS and DPD expression was found. It is concluded that characterizing colorectal carcinomas by TS and DPD expression may disclose subsets of patients with significantly greater risk of disease recurrence and early death. This may be utilized in the selection of patients for treatment approaches and for decision on follow‐up programs. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17096352</pmid><doi>10.1002/ijc.22318</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2007-02, Vol.120 (3), p.694-701
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_20618803
source Wiley-Blackwell Read & Publish Collection
subjects Aged
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Chemotherapy, Adjuvant
colonic neoplasms
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - enzymology
Colorectal Neoplasms - pathology
dihydrouracil dehydrogenase (NADP)
Dihydrouracil Dehydrogenase (NADP) - metabolism
disease‐free survival
Female
fluorouracil
Fluorouracil - therapeutic use
Humans
Immunohistochemistry
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Staging
Pharmacology. Drug treatments
predictive value of tests
Prognosis
Survival Analysis
survival rate
thymidylate synthase
Thymidylate Synthase - metabolism
Treatment Outcome
Tumors
tumour markers, biological
title The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5‐fluorouracil
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A25%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prognostic%20significance%20of%20thymidylate%20synthase%20and%20dihydropyrimidine%20dehydrogenase%20in%20colorectal%20cancer%20of%20303%20patients%20adjuvantly%20treated%20with%205%E2%80%90fluorouracil&rft.jtitle=International%20journal%20of%20cancer&rft.au=Jensen,%20S%C3%B8ren%20Astrup&rft.date=2007-02-01&rft.volume=120&rft.issue=3&rft.spage=694&rft.epage=701&rft.pages=694-701&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.22318&rft_dat=%3Cproquest_cross%3E20618803%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4198-4ddc33b32ea80899a2ecdcf7cb39f70c5b83c8fb2aefa0ebee91fe563765690f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20618803&rft_id=info:pmid/17096352&rfr_iscdi=true